CORT Stock Analysis: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$39.87
-4.74 (-10.63%)
▼
5d:
-9.35%
30d:
-43.2%
90d:
-44.66%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Feb 25, 2026
22d
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
8 traders called CORT this week
62% bullish • 5 bearish
62% bullish • 5 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$11.33
Based on -8.7% avg growth
INTRINSIC VALUE TODAY
$7.03
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $39.87, which is considered fair relative to its 30-day fair value range of $30.19 to $66.01. The stock's valuation (Forward PE: 54.5) is in line with its historical norms (58.5). Remarkably, the market is currently pricing in an annual earnings decline of 2.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CORT is in a strong downtrend. Immediate support is located at $33.80, while resistance sits at $47.06. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: CORT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $94.20 (+136.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CORT is in a strong downtrend. Immediate support is located at $33.80, while resistance sits at $47.06. Short-term momentum is weak, with the stock down 10.6% recently.
Market Sentiment: CORT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $94.20 (+136.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$30.19 -
$66.01
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
78.6%
Protect Your Profits
Holding CORT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-10.6%)
- BULLISH: Trading 136.3% below Wall St target ($94.20)
- CAUTION: Recommendation downgraded due to -9.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$30.19 -
$66.01
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$33.80
Resistance Level
$47.06
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
54.47
Wall Street Target
$94.20
(+136.3%)
Revenue Growth (YoY)
13.7%
Earnings Growth (YoY)
-61.0%
Profit Margin
14.3%
Valuation Discount vs History
-2.4% cheaper
PE vs Historical
54.5 vs 58.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.4%
(market-implied from PE analysis)
1-Year Target
$38.91
(-2%)
2-Year Target
$37.98
(-5%)
3-Year Target
$37.07
(-7%)
3-Yr Target (if PE normalizes)
(PE: 54→59)
$39.81
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 54.5, Growth: -21.4%)
$29.07
(+-27%)
Base:
(SPY PE: 22.3, Growth: -21.4%)
$11.90
(-70%)
Bear:
(PE: 19.0, Growth: -21.4%)
$10.11
(-75%)
📈
Valuation based on Current Earnings
Trailing PE: 52.70 | Current EPS (TTM): $0.87
Bull Case
$42.44
(+6%)
Analyst growth -15.9%, PE expands to 58.0
Base Case
$38.58
(-3%)
Market implied -15.9%, PE stable at 52.7
Bear Case
$31.18
(-22%)
Severe decline -20.0%, PE contracts to 44.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 54.5 to 58.5
Stabilization Target:
$42.82
(+7.4%)
PE Expansion Potential:
+7.4%
Last updated: February 01, 2026 9:37 PM ET
Data refreshes hourly during market hours. Next update: 10:37 PM
Data refreshes hourly during market hours. Next update: 10:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Daniel N Swisher Jr
SELL
2200 shares
2025-10-10
William Guyer
SELL
20000 shares
2025-10-07
Joseph Douglas Lyon
SELL
5000 shares
2025-10-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 52 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 59 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 62 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 56 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$34 | 51 HOLD |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
